A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

Study Overview

The purpose of this study is to determine if epigenetic priming with DNA methyltransferase inhibitors (DMTi) prior to chemotherapy blocks is safe and effective in treating children with acute myeloid leukemia (AML).

Study Description

The purpose of this study is to compare the good and bad effects of giving either azacitidine OR decitabine before the usual chemotherapy regimen for childhood AML.


  • IRB Number: 1905866854
  • Research Study Identifier: TX10534
  • Principal Investigator: Batra Sandeep, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176